Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | FAAH | O00519 | 12/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895139 | 1.00 | NPC1 (0.65) | NPC1RAB9AFAAHALDH1A1KDM4E | |
| SCHEMBL13028753 | 1.00 | NPC1 (0.65) | NPC1RAB9AFAAHALDH1A1KDM4E | |
| SCHEMBL11151343 | 0.83 | RAB9A (0.59) | NPC1RAB9AFAAHALDH1A1MEN1 | |
| SCHEMBL2899558 | 0.83 | EPHX2 (0.53) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL13028751 | 0.83 | EPHX2 (0.53) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL2899559 | 0.83 | EPHX2 (0.53) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL11156142 | 0.78 | FAAH (0.50) | NPC1RAB9AFAAHKDM4EMEN1 | |
| SCHEMBL2097993 | 0.77 | RAB9A (0.50) | NPC1RAB9AFAAHALDH1A1KDM4E | |
| SCHEMBL2095091 | 0.76 | SMN1; SMN2 (0.67) | NPC1RAB9AFAAHALDH1A1KDM4E | |
| SCHEMBL27830667 | 0.75 | RAB9A (0.48) | NPC1RAB9AFAAHALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | claimed |
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | RANBAXY LABORATORIES LIMITED (IN) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286211-A1 | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS | OXA1L, PDK4, MLYCD | NPC1 3916/4885RAB9A 4328/4885FAAH 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.